dc.contributor.author |
Idilman, Ramazan |
|
dc.contributor.author |
Demir, Mehmet |
|
dc.contributor.author |
Aladag, Murat |
|
dc.contributor.author |
Erol, Cihan |
|
dc.date.accessioned |
2019-06-19T08:33:00Z |
|
dc.date.available |
2019-06-19T08:33:00Z |
|
dc.date.issued |
2018 |
|
dc.identifier.citation |
Idilman, R. Demir, M. Aladag, M. Erol, C.(2018). Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis c patients cohort.Cilt:26. Sayı:6 666-674ss. |
tr_TR |
dc.identifier.uri |
http://hdl.handle.net/11616/11461 |
|
dc.description.abstract |
The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.
Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma. |
tr_TR |
dc.language.iso |
eng |
tr_TR |
dc.publisher |
Journal of vıral hepatıtıs |
tr_TR |
dc.relation.isversionof |
10.1111/jvh.13075 |
tr_TR |
dc.rights |
info:eu-repo/semantics/openAccess |
tr_TR |
dc.subject |
cirrhosis |
tr_TR |
dc.subject |
direct-acting antivirals |
tr_TR |
dc.subject |
hepatitis C virus |
tr_TR |
dc.subject |
hepatocellular carcinoma |
tr_TR |
dc.subject |
liver transplantation |
tr_TR |
dc.title |
Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis c patients cohort |
tr_TR |
dc.type |
article |
tr_TR |
dc.contributor.department |
İnönü Üniversitesi |
tr_TR |
dc.identifier.volume |
26 |
tr_TR |
dc.identifier.issue |
6 |
tr_TR |
dc.identifier.startpage |
666 |
tr_TR |
dc.identifier.endpage |
674 |
tr_TR |